Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$11.54 USD
-0.10 (-0.86%)
Updated Jul 26, 2024 01:54 PM ET
After-Market: $11.52 -0.02 (-0.17%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
AVTX 11.54 -0.10(-0.86%)
Will AVTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AVTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AVTX
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?
AVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for AVTX
The 3 Best Personalized Nutrition Stocks to Buy Now
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
Avalo Therapeutics appoints Doyle as Chief Medical Officer
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1? mAb, to Treat Hidradenitis Suppurativa
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer